InDex Pharmaceuticals Holding AB (publ) interim report January – September 2018
Directed share issue strengthens the cash position ahead of the CONDUCT resultsPeriod July – September 2018 · Revenues amounted to SEK 0.0 (0.0) million · Operating result amounted to SEK –15.1 (–13.3) million · Result after tax amounted to SEK –15.1 (–13.1) million, corresponding to SEK –0.24 per share (–0.21) before and after dilution · Cash flow from operating activities amounted to SEK –16.1 (–16.6) million Period January –September 2018 · Revenues amounted to SEK 0.1 (0.1) million · Operating result amounted to SEK –59.9 (–50.7) million · Result after tax